Do you want BuboFlash to help you learning these things? Or do you want to add or correct something? Click here to log in or create user.

The three anti-TNF agents approved for CD are infliximab, adalimumab, and certolizumab. Because certolizumab is pegylated, it should have very little, if any, placental transfer and therefore is favored by some clinicians in a pregnant patient over the other two agents.
If you want to change selection, open document below and click on "Move attachment"


owner: ELBOMBARDO - (no access) - MKSAP_17.pdf, p2619


statusnot read reprioritisations
last reprioritisation on suggested re-reading day
started reading on finished reading on



Do you want to join discussion? Click here to log in or create user.